Endonovo Therapeutics Inc (ENDV)
0.0008
0.00 (0.00%)
USD |
OTCM |
Jun 14, 16:00
Endonovo Therapeutics Enterprise Value: 7.350M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | 7.350M |
| June 13, 2024 | 7.386M |
| June 12, 2024 | 7.350M |
| June 11, 2024 | 7.368M |
| June 10, 2024 | 7.386M |
| June 07, 2024 | 7.420M |
| June 06, 2024 | 7.455M |
| June 05, 2024 | 7.420M |
| June 04, 2024 | 7.420M |
| June 03, 2024 | 7.386M |
| May 31, 2024 | 7.455M |
| May 30, 2024 | 7.490M |
| May 29, 2024 | 7.420M |
| May 28, 2024 | 7.525M |
| May 24, 2024 | 7.525M |
| May 23, 2024 | 7.525M |
| May 22, 2024 | 7.560M |
| May 21, 2024 | 7.543M |
| May 20, 2024 | 7.455M |
| May 17, 2024 | 7.469M |
| May 16, 2024 | 7.63M |
| May 15, 2024 | 7.626M |
| May 14, 2024 | 7.595M |
| May 13, 2024 | 7.770M |
| May 10, 2024 | 7.595M |
| Date | Value |
|---|---|
| May 09, 2024 | 7.944M |
| May 08, 2024 | 7.944M |
| May 07, 2024 | 7.944M |
| May 06, 2024 | 7.836M |
| May 03, 2024 | 7.944M |
| May 02, 2024 | 7.766M |
| May 01, 2024 | 8.014M |
| April 30, 2024 | 7.927M |
| April 29, 2024 | 7.840M |
| April 26, 2024 | 7.990M |
| April 25, 2024 | 7.910M |
| April 24, 2024 | 7.944M |
| April 23, 2024 | 7.944M |
| April 22, 2024 | 7.944M |
| April 19, 2024 | 7.986M |
| April 18, 2024 | 8.060M |
| April 17, 2024 | 7.836M |
| April 16, 2024 | 8.091M |
| April 15, 2024 | 8.091M |
| April 12, 2024 | 7.932M |
| April 11, 2024 | 7.932M |
| April 10, 2024 | 7.900M |
| April 09, 2024 | 8.027M |
| April 08, 2024 | 8.091M |
| April 05, 2024 | 8.091M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.573M
Minimum
Dec 09 2020
19.87M
Maximum
Jul 03 2019
9.254M
Average
8.554M
Median
Jun 01 2021
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 3.382M |
| Palatin Technologies Inc | 19.39M |
| iBio Inc | 30.46M |
| Theriva Biologics Inc | -10.87M |
| Oragenics Inc | 6.996M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.603M |
| Revenue (Quarterly) | 0.006M |
| Total Expenses (Quarterly) | 0.792M |
| Gross Profit Margin (Quarterly) | 49.57% |
| Profit Margin (Quarterly) | -26.80K% |
| Earnings Yield | 647.9% |
| Normalized Earnings Yield | -216.38 |